Does recombinant activated protein C work in patients with severe sepsis?

Critical Care Medicine

Volumn 38, Issue 4, 2010, Pages 1217-1220

  Kalil, Andre C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Activated protein C; Propensity scores; Severe sepsis

Indexed keywords

DROTRECOGIN;

CONFOUNDING VARIABLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INTENSIVE CARE; MEDICAL ETHICS; MEDICAL RESEARCH; METHODOLOGY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; SCORING SYSTEM; SEPSIS; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77950230614     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181d53b63     Document Type: Editorial

References (22)

1. Lindenauer PK, Rothberg MB, Nathanson BH, et al: Activated protein C and hospital mortality in septic shock: A propensity-matched analysis. Crit Care Med 2010; 38: 1101-1107
2. Deeks JJ, Dinnes J, D'Amico R, et al: Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7:iii-x, 1-173
3. Franca LR, Payet S, Lay K, et al: Drotreco-gin alfa's impact on intensive care workload in real life practice: A propensity score approach. Value in Health 2008; 11: 1051-1060
4. Katz MH: Multivariable analysis: A practical guide for clinicians. Second Edition. New York, NY, Cambridge University Press, 2006
5. Rubin DB: On principles for modeling propensity scores in medical research. Phar-macoepidemiol Drug Saf 2004; 13:855-857
6. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-763
7. Cepeda MS, Boston R, Farrar JT, et al: Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158:280-287
8. Glynn RJ, Schneeweiss S, Sturmer T: Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98:253-259
9. Longstreth WT Jr, Fahrenbruch CE, Koepsell TD: Propensity scores for rare outcomes and common treatments. Ann Intern Med 2003; 139:152-153
10. Suissa S: Immortal time bias in observational studies of drug effects. Pharmacoepi-demiol Drug Saf 2007; 16:241-249
11. Suissa S: Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-499
12. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
13. Ely EW, Laterre PF, Angus DC, et al: Dro-trecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
14. Angus DC, Laterre PF, Helterbrand J, et al: The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32:2199-2206
15. Ferrer R, Artigas A, Suarez D, et al: Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180: 861-866
16. Martin G, Brunkhorst FM, Janes JM, et al: The international PROGRESS registry of patients with severe sepsis: Drotrecogin alfa (activated) use and patient outcomes. Crit Care 2009; 13:R103
17. Rowan KM, Welch CA, North E, et al: Dro-trecogin alfa (activated): Real-life use and outcomes for the UK. Crit Care 2008; 12:R58
18. Laterre PF, Wittebole X. Clinical review: Dro-trecogin alfa (activated) as adjunctive therapy for severe sepsis-practical aspects at the bedside and patient identification. Crit Care 2003; 7:445-450
19. Kalil AC, Sun J: Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A Bayesian analysis. PLoS One 2008; 3:e2291
20. Finfer S, Ranieri VM, Thompson BT, et al: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of ac-tivated protein C for persistent septic shock Intensive Care Med 2008 34: 1935-1947 21.
21. University of Versailles: Activated protein C and corticosteroids for human septic shock (APPROCCHS). Bethesda, MD, National Institutes of Health, 2009. Available at http:// clinicaltrials.gov/ct2/show/NCT00625209. Accessed February 1, 2010 22.
22. Zhang J, Yu KF: What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280:1690-1691